Thorac Cancer: Real-world data on advanced or metastatic NSCLC patients with rare mutations

Lung adenocarcinoma is a common type of non-small cell lung cancer ( NSCLC )
.

The study retrospectively included patients with advanced or metastatic non-squamous NSCLC aged> 20 years from 9 tertiary hospitals in South Korea between January 2015 and September 2020, who were confirmed to have rare mutations (BRAF, ROS1, MET, RET).
, HER2, FGFR and NTRK)
.

The study included 118 patients with advanced or metastatic non-squamous NSCLC with rare mutations
.

Clinical features

The median progression-free survival (PFS) and overall survival (OS) of patients with ROS1, RET, MET, ERBB2, and BRAF mutations receiving palliative first-line platinum-based chemotherapy are similar
.

PFS in patients with different mutations

The median OS of patients with BRAF, ERBB2, MET, and RET mutations was 14.
1 months (95% CI: 10.
1-14.
1), 34.
5 months (95% CI: 13.
2-36.
9), and 22.
7 months (95% CI: 1.
7), respectively.
-24.
0) and 29.
8 months (95% CI: 28.
9-61.
3) (p = 0.
006)
.

            OS in patients with different mutations

The median PFS of ROS1 patients who received first-line platinum-based chemotherapy or crizotinib was 10.
0 months (95% CI: 3.
7-16.
4) and not achieved (p = 0.
399), respectively
.

The overall objective response rate (ORR) of patients receiving first-line platinum chemotherapy was 37.
0% (95% CI: 26.
6-48.
5), and the disease control rate (DCR) was 77.
8% (95% CI: 67.
2-86.
3)
.

          ORR and DCR in patients with different mutations

In summary, studies have shown that first-line platinum-based chemotherapy has long-lasting clinical effects on non-squamous NSCLC patients with rare mutations

Original source:

Lee SY, Kim YC, Lee KY, Lee SY, Lee SY, Lee MK, Lee JE, Jang SH, Jang TW, Choi CM.